Pilbara Minerals (ASX: PLS) has delivered its March quarter update, showing it’s well into a transitional phase—wrapping up major expansion works and shifting gears towards optimisation and cost control. While…
Challenger’s Q3 Update: Longer-Term Annuity Sales Drive Growth
Challenger Limited (ASX: CGF) has posted a strong third quarter update, with annuity sales leading the charge and a clear focus on quality over quantity as it continues to reshape…
BHP Powers Through Tough Conditions with Record Copper and Iron Ore Output
BHP (ASX: BHP) has shrugged off a tough operating environment to post record nine-month production of both copper and iron ore, proving once again why it’s considered a heavyweight in…
Pro Medicus AI research deal with UCSF to fast-track medical imaging innovation
Pro Medicus (ASX: PME) has taken another major step in its artificial intelligence (AI) push, announcing a multi-year research collaboration agreement between its U.S. subsidiary, Visage Imaging, and the University…
Bellevue locks in $156.5M placement to boost balance sheet and gold exposure
Bellevue Gold (ASX: BGL) has successfully wrapped up a $156.5 million institutional placement, drawing strong demand from both existing and new investors in Australia and overseas. The raise gives Bellevue…
Accent inks game-changing Sports Direct deal with Frasers
Accent Group (ASX: AX1) just kicked off a bold new chapter, announcing a strategic partnership with UK-based retail giant Frasers Group to bring the Sports Direct brand to Australia and…
Viva Energy 1Q2025 Update: Solid Momentum, Synergies on Track
Viva Energy (ASX: VEA) has kicked off the year with a steady performance, reiterating confidence in hitting its 1H2025 EBITDA (RC) guidance of $270–330 million for its Convenience & Mobility…
EBR Systems Secures FDA Approval for World-First Leadless CRT System
EBR Systems (ASX: EBR) has hit a huge milestone, announcing FDA approval for its WiSE® CRT System—the world’s first and only leadless solution for left ventricular pacing in cardiac resynchronization…
Neuren Locks in FDA Agreement for Phase 3 Trial in Rare Neurological Disorder
Neuren Pharmaceuticals (ASX: NEU) has taken a major step forward, confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS) following a…
DroneShield Secures $32.2M in Repeat Military Contracts in Asia Pacific
DroneShield (ASX: DRO) is riding a wave of momentum, announcing a hefty $32.2 million in new contracts from a returning Asia Pacific military customer. These five standalone deals come via…